# A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

Source: https://onco.cc/trials/nct05968326/  
OnCo record `nct05968326` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Autogene cevumeran and Atezolizumab in pancreatic ductal adenocarcinoma, run by Genentech, Inc., active and no longer recruiting.

## Summary

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC is a phase 2 interventional study registered as NCT05968326 by Genentech, Inc., with 260 participants enrolled, started 2023-10-18 and due to reach its primary completion in 2031-01-01. Interventions recorded: Autogene cevumeran, Atezolizumab and mFOLFIRINOX.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05968326
- Phase: 2
- Setting: A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal Adenocarcinoma
- Sponsor: Genentech, Inc.
- Enrolled: 260

## Sources

- ClinicalTrials.gov NCT05968326: https://clinicaltrials.gov/study/NCT05968326

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Autogene cevumeran](https://onco.cc/drugs/autogene-cevumeran/)
- companies: [BioNTech](https://onco.cc/companies/biontech/), [Flatiron Health (Roche)](https://onco.cc/companies/flatiron-health/)

---
JSON: https://onco.cc/api/v1/entities/nct05968326.json